The in vitro activity of clinafloxacin was studied in comparison with ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, sparfloxacin and trovafloxacin against Acinetobacter baumannii clinical isolates. Clinafloxacin showed a MIC 90 of 4 mg/L, whereas the remaining quinolones showed a MIC 90 equal to or higher than 16 mg/L. MIC 50 determination in the presence of reserpine resulted in a two-fold decrease, except for trovafloxacin, which decreased four-fold, and for moxifloxacin and nalidixic acid, which did not change. The effect of reserpine was most pronounced among strains with a low level of resistance to quinolones. The MIC of clinafloxacin for strains with no mutation in either gyrA or parC genes ranged from 0.008 to 0.25 mg/L. In strains with a single mutation at amino acid codon Ser83 of the gyrA gene, the MIC of clinafloxacin ranged from 0.12 to 1 mg/L, whereas strains with a double mutation, one in the gyrA gene and another in the parC gene, showed a range of MIC of clinafloxacin from 1 to 8 mg/L. Therefore, clinafloxacin shows good activity against strains carrying a single mutation in the gyrA gene, and hence a second mutation is required for the microorganism to express resistance.
Introduction
In the last few years the importance of Acinetobacter baumannii in nosocomial infections has been steadily rising. [1] [2] [3] Several outbreaks, many of them in intensive care units, caused by multiply resistant strains of Acinetobacter spp. have been documented. [4] [5] [6] [7] [8] [9] [10] Previously, quinolones had good activity against Acinetobacter strains 11-14 even compared with expanded-spectrum cephalosporins and aminoglycosides. However, resistance to these antibiotics has rapidly emerged in clinical isolates. [15] [16] [17] [18] Multiply resistant A. baumannii infections are usually treated with imipenem or sulbactam. 19 However, recent data show an emergence of resistance even to these antimicrobial agents. 20 Colistin is among the few antimicrobial agents that can still be used to treat infections caused by multiresistant strains, but this antibiotic can cause nephrotoxicity, neuromuscular blockade and neurotoxicity. 20 Thus, there is a need to find treatment alternatives and the new fluoroquinolones may be a therapeutic option in the treatment of severe infections caused by multidrug-resistant A. baumannii.
New fluoroquinolones are broad-spectrum antibacterial agents that present an enhanced activity in comparison with old quinolones. 21 The protein targets for quinolones are type II topoisomerases (DNA gyrase and topoisomerase IV). 22 Both are tetrameric enzymes with two A subunits and two B subunits, encoded by the gyrA and gyrB genes, respectively, in the case of DNA gyrase, and by the parC and parE genes in the case of topoisomerase IV. 22, 23 There is a region in these genes that is known as the quinolone resistance determining region (QRDR), where mutations associated with the acquisition of quinolone resistance have been located. 22 The mutations that play the most important role in the acquisition of resistance are located in the QRDR of the gyrA and parC genes. 22, 24 Mutations affecting the QRDR of the gyrB gene seem to be more frequent in quinolone-resistant strains obtained in vitro 25 than in clinical isolates.
26,27
Mutations affecting the parE gene are extremely Another mechanism of resistance to quinolones, different from alterations in target proteins, is a decrease in the accumulation of the quinolone, both by decrease in permeability and/or by an increase in the active efflux of the antibiotic. These mechanisms have not been studied in depth in Acinetobacter.
24
Reserpine is a well established inhibitor of efflux pumps among Gram-positive microorganisms, 31 and has recently shown its ability to inhibit an active efflux system in Bacteroides fragilis. 32, 33 Moreover, previous results obtained in our laboratory show its potential to act concomitantly with quinolones against other non-fermenting Gram-negative microorganisms such as Stenotrophomonas maltophilia.
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The main aim of the present study was to compare the activity of clinafloxacin, a novel fluoroquinolone, against clinical isolates of A. baumannii with other quinolones both in the presence and absence of reserpine, and to correlate their activity with mechanisms of resistance. 
Materials and methods

Bacterial isolates
Antimicrobial susceptibility testing
Susceptibility testing was carried out using a broth microdilution assay, in either the absence or the presence of reserpine at a concentration of 25 mg/L, in accordance with the guidelines established by the National Committee for Clinical Laboratory Standards. 36 An inoculum of 5 ϫ 10 5 cfu/mL of each isolate was inoculated on to freshly prepared medium containing serial dilutions of ciprofloxacin and moxifloxacin (Bayer, Leverkusen, Germany), nalidixic acid (Sigma, St Louis, MO, USA), levofloxacin (Hoechst Marion Roussell, Romainville, France), sparfloxacin, (Rhone-Poulenc, Vitry, France), trovafloxacin (Pfizer Ltd, Sandwich, UK) and clinafloxacin (Parke-Davis, Ann Arbor, MI, USA). The quality control strains used were: E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212.
The breakpoints proposed by the NCCLS 36 were used for ciprofloxacin (S р 1 mg/L; R у 4 mg/L); levofloxacin (S р 2 mg/L; R у 8 mg/L); and nalidixic acid (S р 16 mg/L; R у 32 mg/L), whereas the breakpoints proposed for MENSURA 37 (Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos) were used for the quinolones that do not possess a breakpoint established by the NCCLS, 36 as was the case for sparfloxacin
To evaluate the intrinsic activity of reserpine, the MIC for this agent was determined following the procedure mentioned above.
Amplification and DNA sequencing of the QRDR of the gyrA and parC genes
The PCR amplification of the QRDR of the gyrA and parC genes was carried out using the primers and following the conditions previously described. 38, 39 PCR was carried out using a DNA thermal cycler 480 (Perkin-Elmer Cetus, Emeryville, CA, USA). Amplified DNA products were resolved by electrophoresis in agarose gels containing 0.5 mg of ethidium bromide per litre. The PCR product was recovered from the agarose gel and purified with the Concert Rapid Purification System according to the manufacturer's instructions (Gibco-BRL, Life Technologies Inc., Gaithersburg, MD, USA). The sample was then directly processed for DNA sequencing using the dRhodamine Terminator Cycle Sequencing kit and was analysed in an automatic DNA sequencer (Abi Prism 377; PerkinElmer).
Results
The susceptibility of 42 clinical isolates of A. baumanni was determined either in the presence or in the absence of reserpine and the calculated MIC 50 and MIC 90 of different quinolones are shown in Table 1 . Resistant and intermediate strains were classified together as resistant. Clinafloxacin showed better activity than ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, sparfloxacin and trovafloxacin, with a MIC 90 of 4 mg/L of clinafloxacin versus a MIC 90 equal to or higher than 16 mg/L of the remaining quinolones. Overall, 55% of the analysed clinical isolates were resistant to clinafloxacin, whereas 57% were resistant to sparfloxacin and trovafloxacin and 60, 62, 81 and 81% were resistant to moxifloxacin, levofloxacin, ciprofloxacin and nalidixic acid, respectively (Table 1) . When reserpine was added, the percentage of resistance decreased in all cases, except for levofloxacin. Clinafloxacin remained the most active, with 43% resistance, whereas 55% of the strains were resistant to sparfloxacin, trovafloxacin and moxifloxacin. The resistance levels to ciprofloxacin and nalidixic acid decreased to 76 and 79%, respectively (Table 1) .
A two-fold decrease in the MIC 50 of ciprofloxacin, levofloxacin, sparfloxacin and clinafloxacin was observed when it was determined in the presence of reserpine, whereas the MIC 50 of trovafloxacin decreased four-fold, and of nalidixic acid and moxifloxacin the MIC 50 did not change (Table 1) . Nineteen (45.2%) out of 42 clinical isolates of A. baumannii showed a decrease in the MIC of at least one of the quinolones when the MIC was calculated in the presence of reserpine. The effect of the reserpine on the MIC of quinolones was most pronounced among the strains with lower MIC values, including eight out of nine strains (88.9%) with a ciprofloxacin MIC of Ͻ4 mg/L. However, in only two strains (10.5%) of the 19 strains affected by reserpine was the MIC of nalidixic acid decreased in the presence of this compound. The 19 strains varied depending on the quinolone(s) that was affected by this inhibitor ( Table 2) . Only a decrease of at least four-fold was considered to be a real effect of reserpine. The maximal decrease in the MIC, 16-fold for clinafloxacin, was observed in a strain having a MIC of clinafloxacin of 0.5 mg/L in the absence and 0.03 mg/L in the presence of reserpine. In this strain, the MIC of ciprofloxacin, levofloxacin and sparfloxacin also decreased four-fold.
To measure any possible intrinsic antibacterial activity of reserpine, the MIC of this compound was determined. The MIC of reserpine was Ͼ256 mg/L for all the strains included in this study.
The correlation between the mutations in the gyrA and parC genes and the MIC of ciprofloxacin and clinafloxacin are presented in Table 3 . Twenty-two strains had a double mutation, a mutation at the amino acid codon Ser83 in the gyrA gene, which generated a change from Ser to Leu, plus a mutation at the amino acid codon Ser80 of the parC gene, which also produced a substitution to Leu in all of these strains. The range of MICs of ciprofloxacin for these strains was from 32 to 256 mg/L and of clinafloxacin was from 1 to 8 mg/L.
One strain had a double mutation at amino acid codon Ser83 of the gyrA gene, and at the amino acid codon Glu84 of the parC gene; in the latter a change of Glu to Lys was produced. Eleven strains had only a single mutation in the amino acid codon Ser83 of the gyrA gene and the remaining eight strains did not show any mutation either in the QRDR of the gyrA or in the parC genes.
Discussion
A. baumannii is an opportunistic nosocomial pathogen that often shows susceptibility to colistin, imipenem and sulbactam, although a trend towards decreased susceptibility to the last two antibiotics has been observed in most nosocomial strains. 20 This scenario makes it necessary to search for therapeutic alternatives other than colistin to treat nosocomial infections caused by A. baumannii. We have compared the in vitro activity of clinafloxacin with other quinolones, showing that this fluoroquinolone, among the tested quinolones, has better activity against A. baumannii. In fact, the MIC 90 of clinafloxacin was at least four-fold lower than that seen for other quinolones.
The analysis of the mutations in the QRDR of the gyrA and parC genes showed that alterations in Ser83 of GyrA were most frequently found among the strains with a MIC of ciprofloxacin 2 mg/L, whereas a double mutation at the amino acid codon Ser83 of the gyrA gene plus a mutation at the amino acid codon Ser80 of the parC gene was found in strains with a MIC of ciprofloxacin 32 mg/L. These amino acid substitutions were also identified in our previous stud- 38, 39 and by other authors. 40 The substitution at amino acid Ser83 of GyrA to Leu was found in strains with a range of MICs of clinafloxacin from 0.12 to 4 mg/L, although the strain having a MIC of 4 mg/L may possess other mechanisms of resistance to clinafloxacin, which may result in this level of MIC. The strains with a double mutation, one in the gyrA gene and another in the parC gene, showed a range of MICs of clinafloxacin from 1 to 8 mg/L. Therefore, clinafloxacin may retain potentially useful clinical activity against strains carrying a single mutation in the gyrA gene, and a second mutation is required for the microorganism to express higher levels of resistance. All the strains of A. baumannii analysed in this study were able to grow in the presence of 256 mg/L reserpine. Therefore, the effect observed on the MIC of quinolones in the presence of 25 mg/L of this compound was not due to the antibacterial activity of the reserpine.
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The effect of reserpine on the MICs of different quinolones is heterogeneous, affecting from only one quinolone (ciprofloxacin or clinafloxacin) to several quinolones at the same time. It is worth mentioning that the majority of reserpine inhibition is observed in clinical isolates having a MIC of ciprofloxacin equal to or lower than 4 mg/L. Therefore, in a strain with a MIC of ciprofloxacin within the range 0.25-4 mg/L, a decrease in the MIC due to reserpine can clearly be observed. This effect is more difficult to appreciate in a strain already having a MIC of 128 mg/L, since it is not sufficient to decrease the MIC below the previous dilution (64 mg/L). However, the effect of reserpine was also detected among some strains with high levels of resistance to quinolones.
The exact mechanisms of action of reserpine in A. baumannii remain unknown. It could be possible that reserpine affects some hypothetical efflux pumps, as is well established among Gram-positive microorganisms. 31 Previous reports have suggested the ability of reserpine to inhibit an efflux pump of Bacteroides fragilis 32, 33 and Stenotrophomonas maltophilia. 34 However, no direct evidence is available to attribute, unequivocally, the effect of reserpine over A. baumannii to reserpine-inhibited efflux pumps. Therefore, further studies to elucidate this question will be carried out.
In summary, clinafloxacin shows a good activity against A. baumannii, being a potential alternative to conventional treatments. Moreover, in combination with reserpine its activity is clearly enhanced, thus further investigations are required to establish the mechanisms of action of reserpine in A. baumannii. 
